HDT Bio is pleased to announce that the company has been awarded an additional $12.8 million to further advance our vaccine development programs targeting two viral diseases, Crimean-Congo hemorrhagic fever and Nipah. This announcement follows a workshop at HDT's Seattle office and laboratory by representatives from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND) and the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (Biomedical Advanced Research and Development Authority (BARDA). HDT is committed to enhancing global health security through the development and application of innovative vaccine solutions, employing our proprietary self-replicating mRNA technology and LION™ delivery platform.
HDT Bio
Biotechnology Research
Seattle, Washington 4,473 followers
Immune Therapy For All
About us
HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio offers a comprehensive compensation plan which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce. This environment is encouraged by HDT's culture, which supports women in science through our Women+ group, creates inclusive events to highlight the diverse cultures represented by our staff, and with the adoption of an open office environment for all.
- Website
-
http://hdt.bio
External link for HDT Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Seattle, Washington
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Immunology, Virology, Oncology, Infectious Disease, and R&D
Locations
-
Primary
Get directions
1150 Eastlake Ave E
200A
Seattle, Washington 98109, US
Employees at HDT Bio
-
Andre Lieber
Academic Cofounder at HDT Bio
-
Neal Mody
Driving the Future of Healthcare Innovation | MedTech/Life Sciences Investor | Let's Connect and Advance Healthcare Together
-
Darrick Carter
Chief Executive Officer at PAI Life Sciences Inc.
-
Shamini Thiagarajan
Associate Director of Program Management at HDT Bio
Updates
-
HDT Bio’s AMPLIFY platform reduces barriers for the distribution of our vaccines by lowering dosage requirements and increasing stability at refrigeration temperatures. Learn more about our technology here: https://hdt.bio/technology
-
-
Our CSO, Peter Berglund, Ph.D. joined Matthew Pillar of Bioprocess Online and other industry thought leaders to discuss the future of cancer vaccines. Watch here: https://lnkd.in/eD_-KCJT #cancervaccines #healthinnovation
-
-
Our CEO and Co-founder Steven Reed, Ph.D., spoke to Jeff Harmon of Conversations Life Science Leaders Aren't Having Podcast about his background working with infectious diseases and vaccines, the story behind HDT Bio, and what makes our technology so novel, including our cutting-edge repRNA and LION™ platform. Check it out: https://bit.ly/3UQSk65 #RNAvaccines #Cancervaccines #BiotechLeadership
-
-
HDT Bio was recently featured in an article in Scrip Citeline discussing how #RNA therapies and #vaccines will develop in 2024. https://bit.ly/4biocWn #LookingForward #RNAvaccines #Cancervaccines #BiotechLeadership
-
-
Want to learn more about HDT Bio’s mission and technology? Check out this episode of Slice of Healthcare’s BioBreakthroughs podcast, with our Co-founder and CEO, Steven Reed, Ph.D. https://lnkd.in/exCndc6z #RNAvaccine #CancerVaccine #HealthEquity
-
-
#MeetTheTeam – Curt is a seasoned professional in research & life science, spanning discovery to clinical trials. He's served as an adjunct professor for 15+ years teaching various subjects, and he champions global health & equity. Welcome, Curt! hdt.bio/team
-
-
HDT Bio is revolutionizing RNA vaccines, advancing technology and exploring new frontiers for innovation. Our flexible LION™️ platform delivers genetic material for personalized medicine and disease prevention, opening doors to addressing a wide range of diseases. By leveraging LION™️’s T cell-mediated immunological memory responses, we are developing a diverse range of cancer vaccines. Learn more here: https://hdt.bio/pipeline/ #CancerVaccines #Innovation
-
-
At HDT Bio, we are proud to collaborate with organizations and academic institutions like National Cancer Institute (NCI), the Center for Innate Immunity and Immune Disease at University of Washington, and others to investigate our self-replicating #RNA vaccine candidates for infectious disease and cancer. We believe that these partnerships are the key to maximizing access to our life saving technology on a global scale. Learn more here: https://lnkd.in/eZMpHxdd #GlobalPartnerships #Innovation
-
-
#MeetTheTeam - Adam brings 20+ years of quality management expertise in pharma & biotech, with a background in analytical chemistry and a track record of building quality systems & securing regulatory approvals. Welcome, Adam! hdt.bio/team
-